Healthcare provider profile · identity verified

Andre Mikael De Leon, MD

Family Practice · DELAWARE, OH · NPI 1922281633

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	580	156
Levothyroxine Sodium	Levothyroxine Sodium	289	63
Omeprazole	Omeprazole	232	56
Lisinopril	Lisinopril	212	65
Gabapentin	Gabapentin	208	51
Amlodipine Besylate	Amlodipine Besylate	205	62
Losartan Potassium	Losartan Potassium	205	57
Pantoprazole Sodium	Pantoprazole Sodium	193	58
Metoprolol Succinate	Metoprolol Succinate	172	45
Metformin Hcl	Metformin Hcl	160	47
Prednisone	Prednisone	158	110
Sertraline Hcl	Sertraline Hcl	138	31
Metformin Hcl Er	Metformin Hcl	128	37
Furosemide	Furosemide	115	37
Diclofenac Sodium	Diclofenac Sodium	108	33
Hydrochlorothiazide	Hydrochlorothiazide	108	36
Eliquis	Apixaban	105	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	103	19
Duloxetine Hcl	Duloxetine Hcl	101	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	92	27
Bupropion Xl	Bupropion Hcl	90	28
Esomeprazole Magnesium	Esomeprazole Magnesium	84	15
Pravastatin Sodium	Pravastatin Sodium	84	23
Rosuvastatin Calcium	Rosuvastatin Calcium	84	24
Fluoxetine Hcl	Fluoxetine Hcl	77	20
Glimepiride	Glimepiride	75	17
Meloxicam	Meloxicam	75	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	75	11
Simvastatin	Simvastatin	74	22
Carvedilol	Carvedilol	69	20
Famotidine	Famotidine	69	20
Mounjaro	Tirzepatide	68	15
Glipizide Er	Glipizide	66	12
Metoprolol Tartrate	Metoprolol Tartrate	66	18
Ozempic	Semaglutide	62	17
Tamsulosin Hcl	Tamsulosin Hcl	62	20
Clopidogrel	Clopidogrel Bisulfate	61	17
Atenolol	Atenolol	59	17
Clonidine Hcl	Clonidine Hcl	59	14
Potassium Chloride	Potassium Chloride	56	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	54	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	53	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	53	14
Pioglitazone Hcl	Pioglitazone Hcl	51	suppressed
Alprazolam	Alprazolam	48	13
Escitalopram Oxalate	Escitalopram Oxalate	47	15
Albuterol Sulfate Hfa	Albuterol Sulfate	46	21
Baclofen	Baclofen	45	17
Synthroid	Levothyroxine Sodium	45	11
Spironolactone	Spironolactone	44	11
Ezetimibe	Ezetimibe	43	11
Trazodone Hcl	Trazodone Hcl	43	16
Celecoxib	Celecoxib	38	11
Allopurinol	Allopurinol	37	11
Chlorthalidone	Chlorthalidone	37	suppressed
Naproxen	Naproxen	37	19
Oxycodone Hcl	Oxycodone Hcl	37	suppressed
Jardiance	Empagliflozin	36	12
Venlafaxine Hcl Er	Venlafaxine Hcl	36	suppressed
Doxepin Hcl	Doxepin Hcl	35	16
Alendronate Sodium	Alendronate Sodium	34	12
Rybelsus	Semaglutide	33	suppressed
Nystatin	Nystatin	32	11
Oxybutynin Chloride Er	Oxybutynin Chloride	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Buspirone Hcl	Buspirone Hcl	31	13
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Diazepam	Diazepam	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	27	16
Lovastatin	Lovastatin	27	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	26	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	23
Montelukast Sodium	Montelukast Sodium	25	suppressed
Pregabalin	Pregabalin	25	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	24	suppressed
Finasteride	Finasteride	24	suppressed
Glipizide	Glipizide	24	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	21
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	17
Valsartan	Valsartan	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Latanoprost	Latanoprost	21	suppressed
Trulicity	Dulaglutide	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Fluconazole	Fluconazole	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Lidocaine	Lidocaine	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Topiramate	Topiramate	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Primidone	Primidone	13	suppressed
Temazepam	Temazepam	13	suppressed
Colchicine	Colchicine	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Ramipril	Ramipril	12	suppressed
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error